Amazon's announced acquisition of pharmacy firm PillPack has sent a shockwave through retail pharmacy stocks, pharmacy benefits management companies, and drug distribution firms. And the deal isn't even closed yet.
Arsanis shares were absolutely crushed on Thursday after the company provided an update from its midstage trial. The company decided that it will cut and run, ultimately discontinuing its pneumonia trial.
Akebia Therapeutics and Keryx Biopharmaceuticals each saw their shares take a dive on Thursday following news that these two companies had agreed upon a merger.
The Dow's newest component, Walgreens Boots Alliance, reported quarterly earnings Thursday morning that beat estimates, but there were some weaknesses, particularly in same-store sales.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Pain Therapeutics shares were destroyed on Wednesday after a vote from the FDA was announced.
Janney Montgomery Scott has initiated coverage of Selecta Biosciences with a price target that represents huge upside.
Cara Therapeutics shares made a solid gain on Wednesday after the biotech announced positive results from a midstage trial.
Summit Therapeutics is another biopharma company that is paying the price on Wednesday.
Aquinox Pharmaceuticals saw its shares crash on Wednesday after the firm gave a disappointing update for a late-stage trial.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Puma Biotechnology shares were climbing on Tuesday after the company announced that it expects a positive outcome in Europe.
Achaogen shares were crumbling on Tuesday following some mixed news from the FDA regarding its treatment of urinary tract and bloodstream infections.
Achieve Life Sciences saw its shares skyrocket on Tuesday after the company announced positive results from its smoking cessation study.
Infinity Pharmaceuticals shares made a healthy gain early on Tuesday after the firm announced a clinical collaboration with Arcus Biosciences.
